ReviewJournal of inflammation research2026
MicroRNAs in Asthma: A Replication-Based Review of Human Evidence.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a heterogeneous inflammatory airway disease characterized by diverse endotypes, variable clinical severity, and differential treatment responses driven by genetic, epigenetic, and environmental influences. MicroRNAs (miRNAs), as post-transcriptional regulators of gene expression, are central modulators of airway inflammation, remodeling, and immune dysregulation and represent promising candidates for biomarker development and therapeutic targeting. Despite the growing literature on dysregulated miRNAs in asthma, findings remain inconsistent and frequently lack independent validation. Using a structured search strategy covering 2009-2025, we identified 299 records and applied predefined replication criteria to prioritize reproducible associations. Two complementary validation Criteria were implemented: cross-study replication across independent cohorts and discovery-replication study designs addressing clinical heterogeneity. This approach yielded 49 cross-study replicated and 10 discovery-replication validated journal articles, substantially narrowing the field to a focused set of high-confidence miRNA candidates. Among the most consistently replicated miRNAs, miR-146a and miR-1246 emerged as central regulators linked to NF-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.